NCT06079398: An ongoing trial by Ascendis Pharma A/S
This trial is ongoing. It must report results 2 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06079398 |
|---|---|
| Title | A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 Years of Age) With Achondroplasia Followed by an Open Label Extension (OLE) Period |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 23, 2024 |
| Completion date | Dec. 31, 2027 |
| Required reporting date | Dec. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 15, 2026 |
| Days late | None |